INDBInternet News Database 2.5 Updated 1 min ago · 397 sources Show or hide images Light or dark

Early PRRT for Neuroendocrine Tumors: Who Should Get It?

Save Like Comments Compare coverage

Summary

NETTER-2 found longer progression-free survival with first-line PRRT, but experts differ on which patients should receive it early and which should have it reserved for later. Medscape News Europe

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Early PRRT for Neuroendocrine Tumors: Who Should Get It?

    NETTER-2 found longer progression-free survival with first-line PRRT, but experts differ on which patients should receive it early and which should have it reserved for later. Medscape News Europe

Comments

Comments need JavaScript.